You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《新股消息》康諾亞生物(02162.HK)今日起招股 入場費26,918.55元
阿思達克 06-25 09:54
內地生物科技公司康諾亞生物-B(02162.HK)公布招股詳情,計劃發售5,826.45萬股股份,當中約10%在港公開發售,招股價介乎50.5元至53.3元,每手500股,入場費26,918.55元,由今日(25日)起至下周三(30日)公開招股,預計於7月8日上市。摩根士丹利、中金及華泰國際為聯席保薦人。

公司專注於自主發現及開發自體免疫及腫瘤治療領域的創新生物療法,核心產品CM310,用於治療多種過敏性疾病,如中重度特應性皮炎(AD)、中重度嗜酸性哮喘和慢性鼻竇炎伴鼻息肉(CRSwNP)以及潛在慢性阻塞性肺疾病(COPD)。

除核心產品外,公司的管線還包括八種處於不同研發階段的候選藥物,其中五種為臨床階段候選藥物,以及三種處於可進入臨床試驗申請階段。候選藥物目前均處於開發階段。

康諾亞引入達15名基石投資者,包括Invesco Ltd.、UBS Asset Management (Singapore)、Hillhouse Capital及Boyu Capital Opportunities Master Fund等,合共認購1.9億美元股份。

公司預計,以招股價中位數51.9元計,所得款項淨額為28.64億元,約60%用於核心及主要產品的研發及商業化;約15%將用於公司其他在研產品的臨床前評估及臨床開發;約15%支付公司新生產及研發設施的租賃付款;約10%用於公司的一般企業及營運資金用途。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account